Recent research has identified a specific biological mechanism that may explain why females experience more severe ...

New research shows that aging blood can accelerate Alzheimer’s-like changes in the brain, while younger blood may offer ...

Alzheimer’s disease is the most common cause of dementia and most often affects individuals older than 60. Image: PSJ Design ...

The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes ...

Alzheimer’s disease, the most common form of dementia, may be influenced by factors circulating in the blood. In mouse experiments, blood from aged animals accelerated amyloid plaque buildup and ...

Summary: New research shows that blood from older animals can speed up Alzheimer’s-related changes in the brain, while young blood may slow them down. In a long-term experiment, mice engineered to ...

More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative for amyloid plaques in a mid-stage study, marking a return to the ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...

Alzheimer’s disease (AD) is a complex and multifactorial disorder that affects all races and genders. Genetic traits influenced by lifestyle and environment lead to a tremendous amount of ...